Fangsheng Pharmaceutical: Silapragel Tablets Obtain "Drug Registration Certificate"

Fangsheng Pharmaceutical Announcement: The company’s self-developed Silapragel tablets have received drug approval numbers and are now authorized for production. Silapragel was originally developed by Swiss company Actelion and was first approved in the United States in December 2015 under the brand name UPTRAVI. It is used to treat pulmonary arterial hypertension (PAH, WHO Group 1), to delay disease progression and reduce the risk of hospitalization due to pulmonary arterial hypertension.